AUS
NZ
UK
CA
USA
IND
Highlights
- ASX faced a modest dip amid global caution and ex-dividend activity.
- BrainChip Holdings (BRN) soared despite no clear catalyst for its rise.
- Prominent small-cap stocks showcased diverse developments and partnerships.
The Australian Securities Exchange (ASX) began the shortened week on a cautious note, with the ASX 200 slipping slightly. A 0.36% decline was observed, signaling hesitation in the global market. This comes amid the reversal of the anticipated end-of-year “Santa rally.” Despite the recent pullback, the ASX remains on track for its strongest yearly performance since 2021, showcasing an overall gain for the year.
Globally, the US S&P 500 saw a dip on Friday, and this sentiment echoed across Asian markets. Meanwhile, Bitcoin also fell back, trading near $93,560. At home, the local market experienced additional pressure as several major companies went ex-dividend.
Amid the broader downturn, some sectors such as gold and energy showed resilience. For instance, Karoon Energy (ASX:KAR) gained traction, rising 3% alongside an increase in crude oil prices.
BrainChip Holdings’ Exceptional Rise
One of the most intriguing movements on the ASX came from BrainChip Holdings (ASX:BRN), which recorded an astounding 68% rise over five days. The latest trading session added 15% to its tally, despite the absence of any clear announcements or updates from the company. Notably, the ASX inquired with BrainChip regarding the sudden surge, but the company confirmed that no undisclosed information was driving the spike.
Small-Cap Movers and Developments
Small-cap stocks displayed diverse activity. Proteomics International Laboratories (ASX:PIQ) unveiled PromarkerEndo, a groundbreaking blood test for diagnosing endometriosis. The test, which avoids invasive surgery, is expected to launch in 2025. This innovation aims to address a pressing medical challenge, as endometriosis affects many women globally.
Australian Oil Company (ASX:AOK) secured a $300,000 payment under a revised settlement and announced progress on pipeline connections set for January. The company is also exploring new gas opportunities in Australia and Southeast Asia.
Austral Gold (ASX:AGD) announced a toll-processing agreement through its subsidiary Casposo. The deal with Challenger Gold (ASX:CEL) involves processing gold at Casposo’s plant in Argentina starting in late 2025. Upfront payments and monthly fees bolster the agreement, which is backed by a $7 million loan for plant refurbishments.
Notable Updates from Other Companies
Dimerix (ASX:DXB) reached a key milestone in its global trial for a potential kidney disease treatment. Meanwhile, Astral Resources (ASX:AAR) proposed a merger with Maximus Resources (ASX:MXR), aiming to expand its gold resource base in Western Australia.
Additionally, Imricor Medical Systems (ASX:IMR) made strides into the Middle East by securing its first order in Qatar, strengthening its international presence under a five-year partnership.
